Identification of virus resistant tumor cell subpopulations in three-dimensional uveal melanoma cultures

K Valyi-Nagy1, S Dosa, S K Kovacs

  • 1Department of Pathology, University of Illinois at Chicago, College of Medicine, Chicago, IL 60612, USA.

Cancer Gene Therapy
|November 7, 2009
PubMed

Insights

Three-dimensional (3D) melanoma cultures reveal resistance to herpes simplex virus type 1 (HSV-1) oncolysis, unlike 2D cultures. The extracellular matrix (ECM) in 3D models hinders virus spread and replication, offering insights into oncolytic virotherapy resistance.

Area of Science:

  • Oncolytic virotherapy
  • Cancer biology
  • Virology

Background:

  • Melanoma resistance to herpes simplex virus type 1 (HSV-1)-mediated oncolysis is not fully understood.
  • Traditional 2D cell cultures may not accurately reflect in vivo tumor microenvironments.

Purpose of the Study:

  • To investigate melanoma resistance mechanisms to HSV-1 oncolysis using 3D cultures.
  • To compare HSV-1 efficacy in 2D versus 3D melanoma models.
  • To identify factors contributing to tumor cell resistance in a 3D extracellular matrix (ECM) environment.

Main Methods:

  • Infection of 2D and 3D uveal melanoma cell cultures (OCM1, C918) with GFP-expressing HSV-1.
  • Observation of tumor cell viability and viral replication.
  • Analysis of tumor cell invasion and spheroid formation within Matrigel and ECM.

Main Results:

  • Viable melanoma cells persisted in 3D cultures for weeks, unlike complete destruction in 2D cultures.
  • Resistant cells exhibited vasculogenic mimicry, formed multicellular spheroids, or invaded Matrigel.
  • The ECM impaired HSV-1 spread and inhibited viral replication post-entry.
  • Quiescent HSV-1 infections were observed in spheroids, with potential for reactivation.

Conclusions:

  • 3D tumor models are crucial for identifying distinct, resistant tumor cell populations.
  • The ECM plays a significant role in mediating resistance to HSV-1 oncolysis.
  • Understanding ECM-mediated resistance is vital for improving oncolytic virotherapy strategies.

Related Concept Videos